Spectrum of Tendon Pathologies: Triggers, Trails and End-State by Steinmann, Sara et al.
 International Journal of 
Molecular Sciences
Review
Spectrum of Tendon Pathologies:
Triggers, Trails and End-State
Sara Steinmann 1 , Christian G. Pfeifer 1,2, Christoph Brochhausen 3 and Denitsa Docheva 1,4,*
1 Experimental Trauma Surgery, Department of Trauma Surgery, University Medical Center Regensburg,
Am Biopark 9, 93053 Regensburg, Germany; sara.steinmann@ukr.de (S.S.); christian.pfeifer@ukr.de (C.G.P.)
2 Department of Trauma Surgery, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11,
93053 Regensburg, Germany
3 Institute of Pathology, University Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany;
christoph.brochhausen@ukr.de
4 Department of Medical Biology, Medical University-Plovdiv, 15A Vassil Aprilov Blvd., 4002 Plovdiv, Bulgaria
* Correspondence: denitsa.docheva@ukr.de; Tel.: +49 941 943-1605
Received: 13 November 2019; Accepted: 24 January 2020; Published: 28 January 2020


Abstract: The biggest compartment of the musculoskeletal system is the tendons and ligaments.
In particular, tendons are dense tissues connecting muscle to bone that are critical for the integrity,
function and locomotion of this system. Due to the increasing age of our society and the overall
rise in engagement in extreme and overuse sports, there is a growing prevalence of tendinopathies.
Despite the recent advances in tendon research and due to difficult early diagnosis, a multitude of risk
factors and vague understanding of the underlying biological mechanisms involved in the progression
of tendon injuries, the toolbox of treatment strategies remains limited and non-satisfactory. This review
is designed to summarize the current knowledge of triggers, trails and end state of tendinopathies.
Keywords: tendon pathologies; tendinopathy; tendinitis; tendinosis; tendon rupture; risk factors;
tendinopathy management
1. Terminology of Tendon Diseases
Tendon disorders have become very common in today’s athletic and non-athletic population
and account for a substantial proportion of activity-related diseases of the musculoskeletal system.
Due to the increasingly aged demographics of our society with elevated life expectancy and a rise in
engagement of young people in extreme and/or competitive sports, tendinopathies and subsequent
tendon ruptures present a major clinical and financial challenge in modern medicine.
Tendinopathy, the pathological change in the tendon that can be classified as a failure in homeostatic
response of the tendon, is a debilitating condition mainly occurring in the active workplace and in
the sports field, which can end in integrant morbidity and disability. The blanket term “tendinopathy”
is used to describe a broad spectrum of non-rupture clinical burdens affecting tendons of primary,
acute and chronically degenerative tendon pathologies, which are associated with prolonged pain,
impaired performance, swelling and further pathological characteristics [1]. Currently, tendinopathies
are divided into three groups, “tendinosis”, “tendinitis” and “tenosynovitis” [2]. “Tendinosis” describes
preferentially chronic degenerative conditions of the mid-substance tendon resulting from an accumulation
of micro-trauma over time, devoid of inflammatory impact and form the most pathological disorders
affecting tendons [1,3]. The term “tendinitis” has been originally employed to designate any painful tendon
impairment, acute or chronic, associated with intra-tendinous inflammation and presence of inflammatory
cells [1,3,4]. “Tenosynovitis” (also “paratendinitis” and “peritendinitis”) describes the involvement
of the paratenon (paratendinopathy) alone or in combination with tendinosis. This term refers to
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inflammation of the tendinous sheath and is strictly speaking not a classical tendinopathy in which
degeneration is observed within the tendon itself. Finally, spontaneous tendon tears and ruptures without
prior symptoms are summarized as tendon injuries [2] and form the final condition of tendinopathies that
failed to heal, thus resulting in loss of the tendon continuum.
So far, there is no reliable method to detect early tendinopathy and no strategy to ameliorate its
progress. Inevitably, tendinopathies lead to tendon rupture and once this happens, tendon natural
healing is slow, often poorly responding to treatments and requires prolonged rehabilitation in most cases.
Until today, none of the therapeutic options offers satisfactory long-term solutions, meaning that repaired
tendons do not regain their complete strength and functionality [5]. However, the understanding of
tendon biology, degenerative and healing processes, progresses slowly and the development of new
treatment options is therefore insufficient. In this review, we aimed to summarize the current state of
knowledge on tendinopathies including potential triggers, trails, end-state and treatment options.
2. Tendon Structural and Functional Relationship
Tendons and ligaments play a crucial role in the locomotive system [6–9]. In the human body,
there are nearly 4000 different tendons and ligaments. Specifically, tendons are dense connective
tissues and critical components for body posture, integrity and function of the musculoskeletal system,
as they connect muscle (musculotendinous junction) to bone (enthesis) to buffer and transmit forces on
which locomotion is entirely dependent [6,7]. In addition, tendon- or ligament-like structures exist in
some peculiar places, which we often forget about; in the heart (chordae tendineae cordis connecting
the valves to the heart muscle), in the diaphragm (central tendinous region), in the ear’s hearing
apparatus (e.g. stapedial tendon) and in the vocal apparatus (vocal ligaments within the vocal folds).
Tendons are highly structured dense connective tissues which provide stabilization of joints
and are able to store and release elastic energy that allows movement [8,9]. They are mainly composed
of collagen fibers and tendon-resident cells which lie embedded in parallel rows (Figure 1a, Figure 2a)
in a well-organized extracellular matrix (ECM), containing high amounts of proteoglycans. The collagen
fibers confer the tissue biomechanical strength and resistance to tension, whilst the proteoglycans
provide the viscoelastic properties for the tendon [8,9]. Cross-linked tropocollagen forms insoluble
collagen molecules that aggregate into increasing order of microfibrils, fibers, bundles and fascicles [8,9].
The fascicles are ensheathed by a thin layer of loose connective tissue, known as the endotenon,
enabling them to glide and extend to each other. Several fascicles form the whole tendon unit and are
covered by another sheet—the epitenon, a dense fibrillary network of collagen preventing adhesion to
the neighboring tissues [8,9]. This internally hierarchical structure enables the tissue to have a high
tensile force and resilience but also prevents quick damage, whilst the endotenon and epitenon sheets
on one side prevent facile separation under mechanical stress and on the other side, they carry blood
vessels, nerves and lymphatics to deeper portions of the tendon unit [8,9]. The paratenon is the very
outer layer and functions to reduce friction between the tendon and nearby tissues [8,9].
The tendon-resident cell population is composed of approximately 90%–95% of tenocytes
(Figure 2a) which are terminally differentiated and no self-renewable cells of elongated shape that
produce the tendon ECM [6,7]. The remaining 5%–10% of cells in the tendon are tendon stem/progenitor
cells (TSPCs) and tenoblasts, which can proliferate and have the potency to differentiate towards
other mesenchymal lineages and are involved in the tissue repair processes [10]. Their subtypes,
the stage of differentiation and the precise location are still not fully defined due to the lack of gene
markers, that allow precise segregation. In addition, chondrocytes are found in compressive areas
including the enthesis at the junction to bone. Furthermore, endothelial-, perivascular-, smooth muscle-
and neuronal cells are found in the endotenon and epitenon sheets, where vasculature and nerve fibers
run [6,7].
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Figure 1. Tendinopathy-related histopathological characteristics in human tendon tissue. Hematoxylin–eosin
staining of (a) normal tendon tissue and abnormalities such as the (b) presence of chondrocytes, (c) ossification,
(d) calcification of the Achilles tendon (X-ray image), (e) accumulation of adipocytes, (f) myxoid (or mucoid)
degeneration and (g) hypervascularization. (h) Image g) 10 x zoomed in. Scale bars: 200 µm. Arrows indicate
the corresponding feature per image. Images derived from the histopathological archive of Prof. Christoph
Brochhausen, Institute of Pathology, University Regensburg.
Loading and compressive forces regulate the production and degradation of ECM whereas
proteoglycans enable homeostasis of the tendon tissue. In conclusion, it is important to understand
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the complex interplay of loading, structural changes and cell response in healthy tissue when considering
treatment of injured tendons.
Figure 2. Histopathological changes in tendinopathy. (a) Normal tendon tissue, (b) fiber crimping
and kinking, loosening of collagenous matrix, (c) increased proteoglycan (PG)/glycosaminoglycan
(GAG) production and changed cytokine profiles, (d) hypercellularity, (e) apoptosis, (f) presence of
other cell types such as chondrocytes (fibrochondrogenesis), (g) osteocytes (calcification), h) adipocyte
accumulation, i) hypervascularization and j) innervation. Based on Järvinen et al. [25].
3. Tendinopathy: A Challenging Disease
At present, the underlying pathology of tendinopathies is not well defined and their etiology
and epidemiology are basically neither rationally determined nor generally valid. The difficulty lies
within their highly heterogeneous nature which is suggested to be coherent with the multitude of
potential risk factors that are considered to trigger tendon disorders and the wide range of degree.
Furthermore, individual patient characteristics (e.g., age, gender and genes), habits (e.g., alcohol
consumption and smoking) and activity levels contribute to the diverse spectrum of tendinopathies.
Moreover, the variety of symptoms such as pain, tenderness and rigidity, swelling, bulge formation
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within the tendon, redness, warmth, muscle weakness and myalgia, spasticity, cramping and even
asymptomatic conditions provide challenges, since they do not appear uniformly but vary from
case to case. Curative and tailored management relies not only on full understanding of the tendon
pathogenesis but also on appropriate, widely accepted and guiding classification and staging systems,
which would be beneficial for rational and adequate patient-targeted therapy. Based on clinical
and basic scientific studies in humans, Cook and Purdam (2009) established the continuum theory for
pathogenesis of tendinopathy from asymptomatic tendons to tendon injuries claiming that tendon
pathogenesis is a continuum, not an absolute [11]. This concept provides the heterogeneous staging
of tendon pathology and suggests that in response to an acute injury or micro trauma, tendons in
the progress of pathogenesis undergo a cascade of three phases from normal tendons to tendon tear
and rupture. These phases are 1) early reactive tendinopathy (non-inflammatory proliferative response
in cells and matrix) in response to acute overload or trauma, 2) failed healing response and disrepair of
the ECM and finally, 3) terminal degeneration and dysregulation of healing resulting in irreversible
stage of pathology showing major structural and compositional changes, cell death, tissue breakdown
and loss of function with predisposition of the tendon to further injury and rupture [11]. One accepted
key hypothesis is that the interactions between tendon cells and their mechanical environment might
be deterministic for the pathogenesis of tendons. Here, the authors tried to incorporate existing clinical,
histological and imaging information of tendon pathology with the aim to develop a model that can
be continually evaluated and modified according to novel research findings. To date, this model
offers high potential to provide the basis for individual assessment and targeted treatment aligned to
the stage of pathology. Due to failing of proper staging using current error-prone imaging technologies,
classifying cases to specific tendon disease stage is imperfect and the detailed tendon pathology
and mechanisms per stage still remain unknown.
4. Morbidity and Clinical Relevance of Tendinopathies
Tendon disorders are medical conditions including traumatic or overuse injuries and a spectrum
of inflammatory and degenerative tendon changes [7]. Patients affected by acute or chronic tendon
disorders suffer from pain, immobility and as a consequence, a loss of daily activities as well as sport
activities. While tendon ruptures present with sudden onset of pain and loss of function, chronic tendon
diseases often appear with slowly elevating pain and steadily increasing loss of function. Due to
this creeping onset, patients are often diagnosed delayed, treated inadequately and thus, suffer in
the longer term [7].
In general, tendon disorders may be attributed to abnormal tendon loading, abnormal ECM
composition and malfunction alongside altered biological and genetic variations that may consequently
lead to exceedance of tendon’s capacity followed by ruptures [7]. Extrinsic factors such as certain
medications, irradiation or infiltration can cause deterioration of tendons’ biomechanical capabilities [7].
Tendon injuries do not only occur in physically active adults and adolescents but they also appear
among the population with a moderate physical activity. Depending on the injury site, tendon injuries
are even more frequent in elderly and more inactive patients, as seen in rotator cuff tears [12]. Sex
specific injury patterns and incidence can also be observed according to the affected tendon. Noncontact
anterior cruciate ligament (ACL, a tendon-like structure) injury, for instance, was associated with
gender-disparity showing alarmingly higher rate in female athletes [13]. In contrast, Achilles tendon
ruptures are more common in men [14]. Tendinopathies are typically classified by their location since
dependent on the site of injury they exhibit different pathomorphologies and require different treatment
approaches. These are tendinopathies of the upper extremities (e.g., rotator cuff tendinopathy and biceps
tendinopathy) and lower extremities (e.g., patellar tendinopathy and Achilles tendinopathy) [15].
Tendon disorders can occur in any region of the tendon: the tendon insertion, mid tendon
substance, musculotendinous junction or tendon sheath. For example, Achilles tendon ruptures are
diagnosed in 84,000 Europeans annually, with 30% of these being surgically treated [16], and they
usually occur at the insertion site of the tendon. Another common tendon injury is the painful rotator
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cuff tear, mainly in the tendon mid-substance that requires surgical repair, affecting approximately 85
people per 100,000 in the general population [17] with dramatically elevated incidence with increasing
age. Especially in rotator cuff disease, differentiation between full thickness tears, partial articular
sided tears, e.g., Partial Articular Supraspinatus Tendon Avulsion (PASTA) lesions, tendon retraction
and muscle quality is mandatory for correct choice of treatment. However, treatment options in
other pathomorphologies differ depending upon various factors that can be distinguished into
patient immanent factors, injury characteristics and patient extrinsic factors. In the recent decades,
the prevalence of, for example, Achilles tendinopathies and ruptures has risen due to both an increase
in the elderly population and a higher participation in excessive physical activities [18]. In the general
population, the incidence of Achilles tendon ruptures, a typical injury among 30–50 year-old men, is up
to 1%. Achilles tendinopathies appear more frequently, with a lifetime risk of 52% in former elite male
runners and the incidence accounts for 5.9% among sedentary people, 24% among competitive athletes
and 18% among athletes younger than 45 years. Generally, Achilles tendon ruptures occur with different
frequencies at various anatomical locations: 75% at the mid-substance, 10%–20% at the distal enthesis,
and 5%–15% at the myotendinous junction [19]. According to current trends, Patellar tendinopathy
is another common load-induced injury with a prevalence of 45% in volleyball players and 32% in
basketball players [20]. Lateral epicondylitis, which is also known as tennis elbow, is a frequent injury
that not only occurs in athletes but also in the general population with an incidence of 4–7 people
per 1000 per year [21]. Rotator cuff injury runs the full spectrum from injury to tendinopathy to
partial tears, and finally complete tears. Age plays a significant role. Injuries range from 9.7% in
those 20 years and younger, increasing to 50% likelihood of bilateral tears of 60 years old and 62% in
patients of 80 years and older (whether or not symptoms were present) [22].
In sum, tendon demographics are very relevant for modern medicine also considering the overall
aging of human society and thus adding additional pressure to tendon-related science to provide
strategies to improve our current management of tendinopathies.
5. Tissue Changes: Histopathological, Structural, Cellular, Epigenetic, Transcriptomic, Proteomic
and Metabolomic
At the onset, tendinopathy is characterized by tendon stiffness, impaired function, local swelling
and pain. Tendinopathies are exposed by macroscopic failure in the entire tendon structure and material.
In contrast to glistening-white healthy tendons, symptomatic tendons appear more amorphous,
grey-brown, friable and edematous [23,24].
Tendons are known to adapt their structure depending upon their physiological mechanical
environment. Hence, they also respond to pathological stimuli (e.g., risk factors given below)
which interfere and deteriorate the primordial tissue homeostasis creating histopathological changes
of the entire tissue, a condition, which has been extensively described before in many previous
studies and reviews [3,25,26]. To this day, the underlying mechanisms for aberrant rearrangement
remain unclear.
In comparison to normal tendon with well-aligned parallel and compact collagen fibers with
adjacent tenocytes (Figure 2a, Figure 1a), the most prominent changes occur in the disorganization
of the tendon matrix represented by discontinuous, crimped and thinned collagen fibers with loss of
their typical hierarchical structure (Figure 2b). Pathological tendons reveal loss of matrix integrity
by reduction of total collagen content and increased production of ECM components (proteoglycans
and glycosaminoglycans; Figure 2c) that results in tendon stiffening.
Moreover, tendinopathy affects the cell density (hypercellularity; Figure 2d) often being
accompanied by areas of enhanced necrotic or apoptotic cell death (Figure 2e) and abnormal possibly
senescent tenocyte- and nuclei rounding (Figure 2f). Furthermore, resident TSPCs can respond
abnormally to signals changed cytokine and growth factor profiles (e.g., IL-1β, TNFα, MMP-2, -3,
-9, -13, COX2, VEGF and TGF-β), and choose entry into alternative non-tenocyte cell fate. Thus,
resulting ingrowth of exogenous cell types (Figure 2f–h, Figure 1b–h) and metaplasia formation
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including cartilaginous, fibrochondroid (Figures 2f and 1b), bony (ossification, Figures 2g and 1c,d),
or adipocyte (Figure 2h, Figure 1e) transformation. Occasionally, tendon degeneration also involves
mucoid or myxoid degeneration with the development of mucoid fibrin deposit (Figure 1f), as well
as hypervascularity (Figure 2i, Figure 1g,h) and innervation [27,28], which may be accompanied by
inflammatory response and pain.
In addition to our understating of histopathological, structural and cellular changes, in the last
decade, the tendon field has also entered into new research areas such as epigenetics, RNA modifications
(transcriptome and regulatory RNAs) and even proteomics and metabolomics.
Recently, intriguing epigenetic alterations were suggested to be associated with tendinopathies.
Analysis of promotor methylation of the MMP11 gene has revealed significant difference in
the methylation status of a single CpG site (highly frequent regions of DNA, where a cytosine
nucleotide is followed by guanine) 65 base pairs upstream of the MMP11 promoter between patients
with patellar tendinopathy and healthy controls. In turn of the hypermethylation of the MMP11
promotor, the authors speculated that MMP11 substrates would accumulate in the tendon matrix
as the amount of the MMP11 enzyme available for catalysis would be limited. The misbalance of
the protein composition of the tendon matrix will thereby lead to degenerative progression [29,30].
Altered methylation status of CpG islands upstream of the ADAMTS4 gene, but not the TIMP2 gene,
was also associated with human patellar tendinopathy [29,30]. Review analysis of Vitamin C, a known
critical cofactor of collagen synthesis, has also proposed that this vitamin can regulate epigenetic
signatures by enhancing the activity of DNA and histone demethylases in the cell nucleus, thus steering
a cell reprogramming towards more pluripotent state, which may influence the ECM/collagen
homeostasis also in the tendon. However, it remains to be validated experimentally, whether Vitamin
C-dependent epigenetic changes influence tendon physiology and disease.
Transcriptome comparison of aged/degenerative TSPCs to young/healthy TSPCs has shown
a profound shift in their gene expression. Gene ontology analysis of top significantly dysregulated
genes have suggested two main clusters of gene function to be affected: namely, resistance to
and clearance of cellular stress, cell–cell and cell–matrix communication and cytoskeletal dynamics [31].
A follow up study of the microarray data by Popov et al. has shown that several members of the ephrin
receptor family, important for cell–cell signaling, are significantly downregulated in aged/degenerative
cells but interestingly, reconstituted some cellular features such as self-renewability and wound healing
potential are greatly improved. Cross platform analysis of transcriptomic data investigated connections
between age, gender and sex hormones during the development of tendinopathy and identified that
in old males decreased expression of CRABP2 leads to cell proliferation, whereas in old females it
leads to cellular senescence [32]. This study gives the important notion that tendon degenerative
diseases may need to be treated differently in males and females because alternative mechanisms may
be involved [32]. Moreover, a number of studies based on RNA sequencing were recently released,
revealing higher cellular heterogeneity in tendon tissues than ever expected. Using healthy and diseased
tendon samples and then carrying out single cell gene expression analysis, five distinct tenocyte
populations, in addition to endothelial, T- and macrophage cells, were discovered [33]. One group
was enriched with microfibril-associated genes; second was Scleraxis positive, co-expressing high
levels of pro-inflammatory factors; third was a population of fibro-adipogenic progenitors; fourth,
TPPP3/PRG4 double positive chondrogenic group and lastly, smooth muscle mesenchymal cells [33].
The authors also reported that in tendon pathology, there are changes in these cell subpopulations
urging future studies on the precise cellular interplay [33]. Again, based on single cell transcriptomics
and lineage tracing another TPPP3 positive cell fraction co-expressing PDGF receptor alpha was
found and suggested to be acting as resident stem cells in the tendon, which can generate tenocytes
during healing [34]. Interestingly, fibro-adipogenic progenitors were also identified in this study
and suggested to give rise to fibrotic cells and scars during tendon repair. It will be of interest to
compare the TPPP3/PDGF receptor alpha double positive cell to Nestin high population found by
Yin et al., who proposed that these cells are also stem-like with strong tenogenic potential [34,35].
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Transcriptomic studies of mouse Achilles identified 13 unique cell types including four previously
undescribed populations of fibroblasts. Another group proposed that there is also a regional impact,
tendon proper and peritenon, on the tendon subpopulations and their gene profiles. This uncovered
tendon cell heterogeneity may have important implications for our understanding of how tendon
tissue is assembled and maintained in physiology and disease, as well as contributing to the design of
therapies to treat tendinopathies.
In addition to transcriptome analyses, further understanding of post-transcriptional regulation of
gene expression in tendon physiology, disease and repair is also of great importance. Here, identifying
non-coding RNAs such as micro RNA, long- and short-non coding RNAs and examining their
expression and function in tendinopathy will be of relevance [36]. Numbers of studies have initiated
investigation of specific microRNAs in relation to tendon degenerative diseases and reported promising
novel traits [36–42].
Wide characterization of the protein composition and alteration in tendon disease can be gained
via proteomics; however so far, only a few studies focusing on tendon tissue were reported. One group
performed profiling of young, aged and injured tendons and found that young tendons contain
more protein fragments than the aged, suggestive that the protein turnover decreases with age [43].
Furthermore, the authors found distinct regional protein composition of the fascicular and interfascicular
matrix and proposed that the interfascicular matrix has higher turnover [44]. Furthermore, proteomics
of human supraspinatus disease identified marked protein changes to the elastic fiber, fibrillin-rich
and pericellular matrix niches [45]. Additional information related to protein synthesis and degradation
can be yield by metabolomics. Metabolomic profiling of patients with rotator cuff stiffness and tears
showed interesting changes in lipid-related metabolites indicating cholesterol levels may be related to
the rotator cuff pathogenesis [46]. Glucose and lactate metabolisms have been discovered to play a role
in tendon repair as well as in tenogenic differentiation via metabolomic analysis, making this area of
research also attractive for further expansion into tendon-related studies [47,48].
A study released in 2020, dealing with mechanical loading response in hypervascular tendon,
demonstrated a rapid cell-mediated tissue breakdown upon mechanical unloading, in contrast
to unloaded physiologically normal hypovascular tendon [49]. Analyses of tissue transcriptome
and secretome revealed that a stromal niche with elevated tissue oxygenation and temperature drives
a ROS-mediated cellular stress response that leads to adoption of an immune-modulatory phenotype
within the degrading stromal tissue [49]. Degradomic analysis further showed a surprisingly rich set of
active matrix proteases behind the progressive loss of tissue mechanics [49]. This study is an example
of how integrating different large data sets may help us to draw more accurately the interdependent
and complex scenario behind tendon pathophysiology.
Altogether, these new investigatory lines should be followed, as they may yield not only
breakthrough molecular discoveries underlying certain tendinopathies, but also may help us gain
a more integral picture of the different levels: tissue, cellular, DNA, RNA and protein levels, as well
as different regulatory programs affected during progression of tendinopathy.
6. Vasculature, Inflammation and Neurons
The role of vasculature and inflammation in tendinopathy has been controversial and patchy in
literature. Neovessels in the pathogenesis of tendinopathy are still poorly understood [50]. These vessels
differ from vasculature formed during development and tissue growth; they leak and do not have
proper perfusion [50]. Thus, neovessels fail to deliver oxygen and nutrients to tissue regions under
hypoxia [50]. Järvinen et al. [50] has recently postulated a new model for vascular pathogenesis in
tendinopathy where the cells in tendinopathic tendons respond to prevailing hypoxia by secreting
growth factors and attracting angiogenesis and inflammatory cell accumulation. One possibility to
overcome this problem would be to find strategies to stabilize neovessels to functional blood vessels
and thereby returning to normal oxygenation. [50]
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Inflammation in the context of tendon repair has been better addressed and it is accepted to be
necessary for debridement after injury and activation of endogenous cell response, however persistent
inflammation can drive fibrosis and thereby compromise the healing outcome [4]. The ability to
resolve inflammation by the resident cell populations in tendons at an appropriate time would be
crucial for successful outcome. Studies on anti-inflammatory drugs (reviewed in Dakin et al. [4,51])
have reported to induce side effects on the resident cells, as well as on resolving components of
the inflammatory response. Therefore, a prolonged use of such drugs may be a contraindication
as a therapeutic approach [4]. In this area, it would be of great importance to understand the interplay
of immune (macrophages and T-cells) and tendon resident cell populations during the time course of
tendon repair [4]. Identifying strategies to influence the presence, activity and depletion of target cell
populations may establish a novel approach to steer the repair process to a satisfying outcome [4].
On the contrary to inflammation in tendon repair, a debate remains regarding the role of
an inflammatory process in tendinopathy owing to a lack of clinical correlation [52]. Nevertheless,
many studies have highlighted the presence of immune cells and inflammatory mechanisms throughout
the spectrum of tendinopathy in both animal and human models of disease (reviewed by Millar et al. [52]).
In particular, macrophages are becoming more recognized to play a role in tendinopathy. Recently,
macrophage activation pathways have been identified in diseased human rotator cuff. At the early stage
of the disease, interferons and NF-kB were dominant, whilst at the advanced stage of the disease, STAT6
and glucocorticoid receptor signaling pathways were activated [4,53]. Key inflammatory regulatory
molecules, namely cytokines (IL-33), nitric oxide, prostaglandins and lipoxins play a crucial role in
modulating changes in the extracellular matrix within tendinopathy [52].
Neuronal changes, in particular glutaminergic alterations, have been associated in painful
tendinopathy, while sensory neuropeptides have been linked to failed healing and pain (reviewed in
Dean et al. [53]). In clinical terms, glutamate appears important also for tendon healing whilst its
upregulation in tendinopathy appears consistent with persistently failed repair response [53]. However,
little work had been carried out to carefully investigate the effects of glutamate and other neuropeptides
on tendon derived cells and altogether, this area of research is still very fragmented and will require
further investigation on in vitro, in vivo and clinical levels.
Further understanding on the links between vasculature, inflammatory mechanisms, neuronal
alterations in tendon diseases, as well as during healing, needs to be gathered in order to outline
more precisely their impact and to develop novel therapeutics working along these axes for human
tendinopathy [52,53].
7. Biochemical and Biomechanical Alterations
In the recent decades, biochemical and molecular studies of tendinopathy have advanced our
understanding of the underlying degenerative process. It can be considered a failure of matrix
adaptation and remodeling due to an imbalance between matrix decomposition and synthesis due
to a variety of stresses and mechanical loads. The major structural and molecular changes include:
up-regulation of collagen type I and collagen type III mRNA and a shift to a higher collagen
type III abundance in relation to collagen type I in the ECM [54], elevated levels of fibronectin,
tenascin C, glycosaminoglycans (GAGs), aggrecan and biglycan [55,56]. There are also changes in
the activity of various MMPs [29,57–59]. The imbalance between matrix metalloproteinases and their
endogenous inhibitors (TIMPs) is considered to play a crucial role in the degenerative process [60,61].
Downregulation of MMP-3 and upregulation of MMP-2 and vascular endothelial growth factor (VEGF)
was reported in Achilles tendinopathy [62–65]. Tendinopathy also involves an increase in inflammatory
mediators such as prostaglandin E2 and interleukin -1, an enhanced expression of cyclooxygenase
2, growth factors including TGF-β and platelet derived growth factor (PDGF), insulin-like growth
factor-1 (IGF-1) and neurotransmitters such as glutamate and substance P [66–72].
The human tendon has the ability to adapt to loading through an increased collagen synthesis
and MMP activity [57]. This adaptation modifies the mechanical strength and the viscoelastic properties
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and furthermore, decreases the stress susceptibility, which in turn, leads to a higher load resistance.
Nevertheless, the tendon has to withstand tremendous forces during repetitive activities making
the tendon prone to overuse injuries. Over time, repetitive tensile loading under the tendon injury
threshold can lead to an accumulation of micro-injuries, that elevate the risk for tendinopathy and end
up in rupture. As a result of micro-injuries, scattered vascular in-growth including necrotic capillaries
contributes to vascular compromise [73,74]. This leads to local tissue hypoxia which is considered
to increase the risk for degeneration and tendinopathy [75]. Subsequently, aging does not only
alter the tendon mechanical properties but also tendon tissue metabolism [46–48] and the “fitness”
of endogenous tendon cells [31,76,77], a term which is indicative for their native capacity and efficiency
of tendon cells to fulfill their basic functions in the tendon such as evading senescence, responding
to growth factors and cytokines, maintaining tendon cell fate, matrix homeostasis and proper
mechanotransduction. All in all, during aging there is increasing susceptibility for micro-injuries
and thereby prevalence of degenerative changes.
8. Tendinopathy: Variety of Etiological Factors and Disease Triggers, Trails and End-State
The etiology of tendinopathies is known to be multifaceted (Figure 3) which might be one possibility
to explain the different shades of tendinopathy. Traditionally, tendinopathies are proposed to result
from acute traumatic load, repetitive mechanical traumas or overuse beyond the capacity of the affected
tendon. However, tendinopathies are no longer suggested to be an overuse injury per se, but other
promoting factors, alone or in combination, have to be considered as well [78–80]. One possibility
to explain the different shades of tendinopathy is that diverse triggers can initiate the process,
which gradually funnels down to distorted cell–cell and cell–matrix communication and thereby,
the inherent cell and matrix organization of the tendon tissue is lost inevitably leading to tendon
rupture. In this process, exogenous lineage cells can be activated causing vascular and neuronal
in-growth, inflammation and pain but also endogenous tendon stem/progenitor cells can respond
abnormally to signals and choose entry into alternative cell fate, thus resulting in tendinous fattening
and calcification (Figure 3). The changes occurring during tendinopathy are considered a functional
adaptation to the altered mechanical loading. There are three main hypotheses about the reasons for
tendon degeneration: (1) mechanical overuse (via matrix), (2) neo-vascularization (via exogenous cells)
and (3) cell and tissue aging (via endogenous cells). Most likely, all these three triggers cross-talk
and cross–react; however, so far detailed studies on the above have not been carried out in a systematic
fashion. Figure 3 illustrates that tendinopathy is a step-wise development starting from initiating
risk factors and resulting in the end state of tendon rupture. However, to date the precise speed
of disease progression is unknown, since it is impossible so far to diagnose the initial steps due to
the lack of technologies to detect the early changes. Moreover, since it is a multifaceted disease,
the progression speed might be different, for example, in fattening tendinopathy versus calcifying
tendinopathy (Figure 1). The process may also be influenced by age, gender, mobility and overall
health status of the patients. In all, “one size fits all” or averaged kinetics of the entire tendinopathy
process for human populations might be difficult to obtain.
A variety of biological parameters and lifestyle-related factors as well as pharmacological
agents [81] are contemplated to play a major role in the development of chronic tendon pathologies.
Here, we distinguished between mechanical overuse- and load-related triggers, intrinsic (acting from
within the body) and extrinsic (acting on the body) etiological factors (Figure 3).
Moreover, individual biomechanics such as movement kinetics and kinematics, flexibility, foot
posture, neuromuscular capacity and structural anatomy may affect tendinopathy. Tendons become
progressively damaged through repetitive excessive loading, change of load or compression.
Furthermore, the malalignment and imbalance of surrounding muscle tissue, as well as training
errors promote progression risk [53,82,83].
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Figure 3. Schematic representation of tendinopathy pathogenesis. It is hypothesized that various risk
factors including mechanical overuse as well as intrinsic and extrinsic factors can trigger the development of
tendinopathy in a continuous way. The first step is that these risk factors impair proper tendon repair leading
to early reactive tendinopathy, which still harbors the capacity for healing. Furthermore, accumulation
and increase of risk factors lead to tendon disrepair, that subsequently results in tendon degeneratione.
Poor function and load capacity of the tendon finally end up in the end-state of tendinopathy, that leads to
tendon tearing or rupture. Based on Cook and Purdam [11] and Shearn et al. [89].
Besides mechanical risks, which are seen as key initial triggers for tendinopathy, multiple systemic
(intrinsic) factors, which are very individual, seem to have a relevant impact on tendinopathy. Thus,
age and aging, gender, body weight and height, genetics, hormonal background (e.g., menopause),
pre-existing disorders (e.g., obesity, hypercholesterolemia, diabetes mellitus, adiposity, hyperlipidemia
and chronic gouty arthritis) and prior tendon injuries are ranked to influence the biological aspect
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of tendon pathogenesis by reducing the capability of the tendon to tolerate load and by modulating
repair responses [84–86].
Finally, tendon disorders can be triggered by several extrinsic, environmental factors, which are
likely to affect the stress on the tendon tissue from the outside. This includes active daily life
and physically demanding workplace, poor nutrition, smoking, alcohol consumption, environmental
factors (e.g., cold weather and foot wear) and pharmacological agents (e.g., fluoroquinolone
and quinolone antibiotics, corticosteroids, aromatase inhibitors and statins) [87,88].
In summary, the wide-ranging variety of tendinopathy risk factors could provoke a highly diverse
spectrum of local cellular response with subsequent collagen disruption and inflammation that might
be one cause for the broad pathological spectrum. However, the exact mechanisms of how mechanical,
intrinsic and extrinsic factors influence tendinopathy risk are largely unknown due to lack of proper
models that would allow fundamental inference.
9. Current Tendinopathy Management Strategies
Tendon treatment often requires lengthy periods of rehabilitation, especially in the elderly
population since the original biological properties and mechanical strength are rarely fully regained,
and rather, frequently coupled with chronic pain. Ideally, interventions should be tailored to the actual
pathology, as well as patients’ expectations. Clinical management of tendinopathy is challenging. Due to
the multifactorial nature of the disease, interventions are not effective in every patient and robust
and convincing evidence of treatment success for many commonly applied therapies is lacking.
Classical therapeutic approaches have focused on reducing inflammation and pain, yet research
suggests that little to no inflammation is present in the tendons that fail to heal.
The mainstay of first-line management of early (reactive) tendinopathies is conservative
(non-operative) treatment, which comprises modification of activity, relative rest, pain relief using
anti-inflammatory Non-Steroidal Anti-Inflammatory Drugs (NSAID), as well as corticosteroid injections
and cryotherapy (Table 1) [78,90]. The traditional physiotherapy in combination with myofascial
therapy, ultrasound, iono-and phonophoresis and acupuncture yield clinically good results, as long
as no major structural damage can be observed (Table 1) [78,90]. The use of corticosteroids or NSAIDs
for inflammatory suppression and pain relief is controversial based on the high risk of spontaneous
tendon ruptures after local or even systemic drug delivery. Non-operative strategies also include
ultrasound treatment and shock wave therapy, eccentric exercises and low-intensity laser treatment [90].
They are applied in order to promote structural remodeling and repair. However, scientific literature
on non-operative treatment modalities often lacks randomization and blinding and thus, it can only be
compared sparsely, due to the variety of study conditions [78,90].
Many promises are given to treatment of tendinopathies by platelet rich plasma (PRP). Not only
many investigations in different tendinopathies have been undertaken, but also the technique itself
is widespread meanwhile. Up to date, more than 400 growth- and immunomodulating factors are
known to be enclosed in PRP. Nevertheless, current research strategies try to unveil, which factors of
PRP are beneficial and which are not as not every tendinopathy and not every patient benefits from
PRP injections [91,92]. Hence, PRP-based-approach for treating tendinopathy still lacks consistent
results between multiple centers due to high variability of the blood derivatives and not yet precise
characterization of the critical indispensable components and those that are dispensable in the PRP
cocktail [92].
Many promises are given to treatment of tendinopathies by platelet rich plasma (PRP). Not only
many investigations in different tendinopathies have been undertaken, but also the technique itself
is widespread. Up to date, more than 400 growth- and immunomodulating factors are known to
be enclosed in PRP. Nevertheless, current research strategies try to unveil, which factors of PRP are
beneficial and which are not. In addition, not every tendinopathy and not every patient benefits from
PRP injections [91,92]. Hence, a PRP-based-approach for treating tendinopathy still lacks consistent
results between multiple centers, due to high variability of the blood derivatives and imprecise
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characterization of the critical indispensable components and those that are dispensable in the PRP
cocktail [92].
Table 1. Current options of tendinopathy management.
Conservative Management Surgical Management
Biomechanical Therapies Biological Therapies Operative Therapies
Classical physiotherapy:
Deep transverse friction massage
Myofascial manipulation
Controlled motion
Ultrasound
(0.75-3.0 MHz; pulsed or continuous)
Ionophoresis
Phonophoresis
Acupuncture
Electrical and laser stimulation:
Pulsed electromagnetic fields
Extracorporeal shock-wave therapy
Laser treatment (pulsed or continuous)
Stabilization and modification:
Taping
Splinting
Bracing
Straps
Orthotic devices
Modification of activity:
Rest
Eccentric exercises
Thermic treatments:
Cryotherapy (e.g., ice packs and baths)
Thermotherapy (heat)
Pharmaceutical agents:
Anti-inflammatory drugs (NSAIDs)
Systemic corticosteroids
Pain control (anesthetics)
Antibody therapy (e.g., IL-17, IL-1β
antagonist and BMP)
Peritendinous (high volume) injections:
Corticosteroid injection
Saline injection
Hyaluronic acid injection
Botulinum toxin (BTA) injection
MMP inhibitor injection (e.g., Aprotinin)
Prolotherapy
Topical glyceryl trinitrate therapy
Polidocanol injection
Glycosaminoglycan polysulfate injection
Sclerosant injection
Low-dose heparin
Blood-based therapies:
Platelet-rich plasma injection
Autologous blood injection
Actovegin (deproteinized extract of
calf’s blood)
Cell-based therapies:
Autologous tenocyte implantation
(Orthocell)
Arthroscopy
Debridement and decompression
Endoscopic/minimally invasive surgery
Percutaneous longitudinal tenotomy
Radiofrequency microtenotomy
Stripping and destruction of neovessels
Endoscopic tendon debridement
Tenolysis
Gastrocnemius recession
Tendon replacement strategies
after rupture:
Tendon allografts
Tendon transfer
Tendon prosthesis
An emerging and potent cell-based strategy for treatment of chronic degenerative tendon
injuries is the autologous tenocyte implantation (Ortho-ATI) developed by Orthocell [93]. For this,
the patient’s own tenocytes are extracted from healthy patellar tendon biopsy, expanded and delivered
to the diseased tendon site via ultrasound guided injection under local anesthetic to stimulate tendon
regeneration [94,95].
If degeneration has progressed to degenerative tendinopathy and end stage tendon rupture,
scientific evidence has stated that nonsurgical treatment is less successful as only 60% of the rehabilitated
tendons are functional. Dependent on anatomic location of the tendinopathy, 10%–30% of patients
need to be subsequently treated by surgery after failure of conservative therapies [96]. In addition,
patient immanent factors such as age, co-morbidities and local degeneration need to be taken into
account, in order to offer a tailored treatment strategy.
Around 30% of Achilles tendon injuries require surgical treatment, including suturing,
implantation of autologous tissue (e.g., strip of the central aponeurosis of gastrocnemius,
peroneal tendon, fascia lata, flexor digitorum longus or flexor hallucis longus), an allograft or a synthetic
scaffold. However, there are limitations associated with these treatment options. Autologous tissue has
a limited availability and is associated with a high risk of donor site morbidity. Allografts have limited
availability and are expensive due to costs associated with tissue banking, required microbiological
testing and method of processing [4]. Synthetic grafts lack natural tissue organization and consequently
have low bio-integration and biomechanical capacities often resulting in unsatisfactory results. After all,
not only does the tendon substance need to be restored, but also the function that was lost due to
the tendon rupture.
A new strategy that is being experimentally and pre-clinically explored is tendon tissue engineering,
which relies on the application of effective cells injected directly to the site of tendon lesion or on
the delivery of cells seeded on a suitable carrier, such as hydrogel or dense matrix in order to speed
up the restorative process [97–100]. However, few treatments for tendinopathy are targeted against
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specific molecular processes. In most cases, there is little to no evidence of therapeutic effectiveness
especially in the long term.
Cook et al. have proposed to implement the continuum model of tendinopathy to help guide
targeted clinical treatments and thus to lead to improved patient outcomes [11,79]. The continuum
model proposed a staging of tendinopathy based on the changes and distribution of disorganization
within the tendon tissue with the aim to support clinicians to understand the various presentations
of tendinopathy and to allow rational placement of clinical interventions [79]. However, this model
did not integrate pain and the nervous system with the pathology. Hence, the authors proposed
a revised continuum model encompassing structure, function and pain relationships, which can advise
the choice of therapy; concretely, interventions addressing pain, poor function and load capacity
depending on the stage of disease [79]. This study points towards the need to generate rationalized
algorithms in decision making during management of tendinopathies, which may help to gain more
cross-comparative study data from multiple clinical centers worldwide [79].
The current low success rate of therapeutic strategies directly reflects on one side, the deficiencies in
comprehensive understanding of the molecular and cellular mechanisms controlling the tendinopathy
process as well as on the other side, the further necessity of improvement in clinical management of
tendinopathy by limiting the design of smart, tendon-specific strategies for countering the advancement
or even preventing the onset of tendon degeneration.
10. Conclusions
Despite the significant progress in tendon research, to date, the management of tendinopathies is
restricted to symptomatic therapy. Tendon-specific treatment options are still unavailable mainly because
of our incomplete understanding of underlying molecular and cellular mechanisms and preceding risk
factors. Some ongoing challenges of clinicians and researchers are identification of such prospective risk
factors and early detection of the disease as well as defining effective strategies to attenuate the disease
process. In the area of disease detection, innovative imaging techniques will be of great interest, whilst in
the area of prevention and prophylaxis, investigating how modifying the disease risk factors might
reduce the danger for developing tendinopathy and occurrence ng of tendon injury will be very relevant.
The tendon research field should also pursue a more systematic way to decipher the complexity behind
tendon degeneration. Research on how influencing the fate of endogenous cells and the activity
and prevalence of exogenous cells affects the tendon tissue at times of homeostasis and repair, may lead
to the outlining of very innovative ways to combat tendinopathies. The recent great advancement
in technologies like RNA sequencing, proteomics, metabolomics, tissue engineering, nanoparticles
and organ-on-chip integrated with big data analysis and computational modeling should be more
strongly adopted by tendon scientists. We believe that based on joint research efforts and combining
multidisciplinary knowledge and expertise, we will experience in the near future the identification
of drug targetable components that counter tendinopathy or even boost tendon healing, as well
as a significant innovation in cell-based therapy and in creating functional three dimensional tendon
mimetics to be implemented in regenerative medicine. In turn, the long-awaited new era of improved
clinical outcomes in tendinopathy management shall begin.
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Abbreviations
ACL Anterior cruciate ligament
ADAMTS A disintegrin and metalloproteinase with thrombospondin motifs
CpG Cytosine nucleotide followed by a guanine in the DNA along its 5′ → 3′ direction
COX2 Cyclooxygenase-2
CRABP Cellular retinoic acid-binding protein
DNA Deoxyribonucleic acid
ECM Extracellular matrix
GAGs Glycosaminoglycans
IGF Insulin growth factor
IL Interleukin
MMP Matrix metalloproteinases
NF-kB Nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells
NSAID Non-steroidal anti-inflammatory drugs
PASTA Partial articular supraspinatus tendon avulsion
PDGF platelet derived growth factor
PGs Proteoglycans
PRG4 Proteoglycan 4 or lubricin
PRP Platelet rich plasma
RNA Ribonucleic acid
STAT6 Signal transducer and activator of transcription 6
TGF-β Transforming growth factor β
TIMPs Tissue inhibitor of metalloproteinases
TNFα Tumor necrosis factor-α
TPPP3 Tubulin Polymerization Promoting Protein Family Member 3
TSPCs Tendon stem progenitor cells
VEGF Vascular endothelial growth factor
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